| Target | Inhibitor name | Treatment-related adverse events | Immune-related adverse events |
| PD-1 | Nivolumab | Fatigue, decreased appetite, nausea, musculoskeletal pain, diarrhea, rash | Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction, encephalitis, rash | Pembrolizumab | Fatigue, decreased appetite, nausea, musculoskeletal pain, diarrhea, rash, pruritus, constipation | Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction | PD-L1 | Atezolizumab | Fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, constipation | Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), meningitis/encephalitis, pancreatitis, dermatitis/rash | Durvalumab | Fatigue, decreased appetite, nausea, urinary tract infection, diarrhea, musculoskeletal pain, constipation, peripheral edema | Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis | Avelumab | Fatigue, decreased appetite, nausea, urinary tract infection, musculoskeletal pain | Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction |
|
|